To understand Aflac (NYSE:AFL), the first thing you have to realize is that the company does much more than just offer supplemental insurance in the U.S. market. Aflac's primary business is in Japan, where it serves a larger market and produces more of its revenue and profit than its domestic operations do. Coming into Tuesday's fourth-quarter financial report, Aflac investors wanted to see continuing signs of solid growth in revenue and earnings, but the insurer didn't produce the growth in operating earnings that it had hoped to achieve. Let's look more closely at Aflac to see what its results say about the company going forward.
Image source: Aflac.
Aflac posts mixed resultsAflac's fourth-quarter results showed the impact of the different conditions the insurer faces in its worldwide operations. Total revenue jumped 12% to $5.96 billion, which was nearly double the growth rate that most investors were expecting to see in Aflac's top line. Net earnings, however, were up only 3% from year-ago levels. Using Aflac's favored operating earnings measure and adjusting for currency impacts, the insurer's bottom-line figure of $1.46 per share was $0.17 less than the consensus forecast among those following the stock.
Top 5 Heal Care Stocks For 2019: Cytokinetics, Incorporated(CYTK)
Advisors' Opinion:- [By Logan Wallace]
Cytokinetics (NASDAQ:CYTK) had its price target cut by investment analysts at Piper Jaffray Companies to $13.00 in a note issued to investors on Monday. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective would indicate a potential upside of 55.69% from the stock’s previous close.
- [By Max Byerly]
Get a free copy of the Zacks research report on Cytokinetics (CYTK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Cytokinetics (CYTK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 5 Heal Care Stocks For 2019: Aluminum Corporation of China Ltd(ACH)
Advisors' Opinion:- [By Logan Wallace]
Banco de Sabadell S.A acquired a new position in Aluminum Corp. of China Limited (NYSE:ACH) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 25,227 shares of the basic materials company’s stock, valued at approximately $340,000.
- [By Max Byerly]
Aluminum Corp. of China Limited (NYSE:ACH) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company.
- [By Ethan Ryder]
Shares of Aluminum Corp. of China Limited (NYSE:ACH) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.70 and last traded at $10.71, with a volume of 2367 shares trading hands. The stock had previously closed at $11.00.
- [By Ethan Ryder]
Aluminum Corp. of China Limited (NYSE:ACH) has been assigned a consensus recommendation of “Hold” from the eight research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company.
Top 5 Heal Care Stocks For 2019: Cardiome Pharma Corporation(CRME)
Advisors' Opinion:- [By Stephan Byrd]
Here are some of the media stories that may have impacted Accern’s rankings:
Get Cardiome Pharma alerts: Cardiome Pharma Corp (TSE:COM): Should The Recent Earnings Drop Worry You? (finance.yahoo.com) Pacira Pharmaceuticals Gets a Hold Rating from Canaccord Genuity (analystratings.com) As of May, 21 Analysts See $-0.20 EPS for Cardiome Pharma Corp. (CRME) (thecasualsmart.com) Cardiome Pharma Corp. (CRME) stock added 0.33% off its SMA-20 (thestocksnews.com) Cardiome Pharma (CRME) Upgraded to Sell at ValuEngine (americanbankingnews.com)Shares of CRME traded down $0.01 during mid-day trading on Wednesday, reaching $2.29. The company’s stock had a trading volume of 730 shares, compared to its average volume of 138,610. The firm has a market cap of $80.20 million, a price-to-earnings ratio of -2.53 and a beta of 0.19. The company has a debt-to-equity ratio of 2.47, a quick ratio of 3.99 and a current ratio of 4.80. Cardiome Pharma has a 52 week low of $2.28 and a 52 week high of $2.30.
- [By Logan Wallace]
Cardiome Pharma Co. (TSE:COM) (NASDAQ:CRME) – Stock analysts at Zacks Investment Research issued their Q2 2018 EPS estimates for Cardiome Pharma in a research note issued on Tuesday, May 22nd. Zacks Investment Research analyst J. Vandermosten anticipates that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter.
- [By Lisa Levin]
Cardiome Pharma Corp. (NASDAQ: CRME) is expected to post quarterly loss at $0.07 per share on revenue of $6.34 million.
Quest Resource Holding Corporation (NASDAQ: QRHC) is estimated to post quarterly loss at $0.09 per share on revenue of $24.85 million.
Top 5 Heal Care Stocks For 2019: QuinStreet, Inc.(QNST)
Advisors' Opinion:- [By Joseph Griffin]
QuinStreet (NASDAQ:QNST) Director James R. Simons sold 229,718 shares of the company’s stock in a transaction on Thursday, May 17th. The stock was sold at an average price of $12.39, for a total transaction of $2,846,206.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
- [By Max Byerly]
Schwab Charles Investment Management Inc. boosted its holdings in shares of QuinStreet Inc (NASDAQ:QNST) by 41.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,823 shares of the technology company’s stock after purchasing an additional 29,306 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.22% of QuinStreet worth $1,275,000 at the end of the most recent quarter.
- [By Dan Caplinger]
The mood was negative on Wall Street on Wednesday, and most major benchmarks finished in the red. Strength in the technology sector wasn't enough to lift more cyclically focused benchmarks like the Dow Jones Industrial Average, and the combination of an attack on Saudi Arabia that sent oil prices higher and some disquieting readings on the inflation front kept investors from feeling more confident about stocks going into earnings season. In addition, some individual companies had bad news that sent their shares lower. Analogic (NASDAQ:ALOG), QuinStreet (NASDAQ:QNST), and MSC Industrial Direct (NYSE:MSM) were among the worst performers on the day. Here's why they did so poorly.
Top 5 Heal Care Stocks For 2019: Chimerix, Inc.(CMRX)
Advisors' Opinion:- [By Joseph Griffin]
Chimerix Inc (NASDAQ:CMRX) Director Ernest Mario sold 45,000 shares of the firm’s stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $4.80, for a total value of $216,000.00. Following the transaction, the director now owns 12,905 shares of the company’s stock, valued at $61,944. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
No comments:
Post a Comment